ReNeuron Group plc Director/PDMR Interest in Share Options (5952P)
20 Octubre 2021 - 1:00AM
UK Regulatory
TIDMRENE
RNS Number : 5952P
ReNeuron Group plc
20 October 2021
ReNeuron Group plc
("ReNeuron" or the "Company")
Director/PDMR Interest in Share Options
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, announces that the
following share option grants have been awarded today under the
Company's Long Term Incentive Plan (the "Plan") and Non-Executive
Share Option Scheme (the "NED Plan") to certain directors listed
below.
An award of 200,000 share options has been granted to Iain Ross
under the NED Plan in accordance with his letter of appointment;
100,000 of the options have been granted with a nominal exercise
price of one (1) pence each and 100,000 of the options have an
exercise price of 107.0 pence each (being the closing mid-market
price of the Company's shares on the last business day before
Iain's date of appointment). The options vest on a straight line
basis over three years and are exercisable if the share price of
the Company's shares exceeds 200 pence for a period of 30
consecutive days subsequent to the award.
An award of 464,136 share options has been granted to Catherine
Isted under the Plan in accordance with her letter of appointment
with all options vesting from the third anniversary of the award;
232,068 of the options have been granted with a nominal exercise
price of one (1) pence each and are exercisable if the Company's
shareholder return meets or exceeds that of the FTSE AIM Healthcare
Index in any three-year period from date of grant; 232,068 of the
options have an exercise price of 94.8 pence each (being the
closing mid-market price of the Company's shares on the last
business day before Catherine's date of appointment) and are not
subject to any performance conditions.
An award of 83,578 share options has been granted to Olav
Hellebø under the Plan in connection with the Company's
remuneration policy whereby executive Directors are eligible to
earn a non-cash bonus payable in the form of share options based on
the achievement of certain objectives in the year to 31 March 2021.
In line with the terms of the Plan and the Company's remuneration
policy, these share options are exercisable from the second
anniversary of the award and are not subject to performance
conditions. The number of options granted is determined by the
equivalent cash value of the bonus earned divided by the market
value of shares, in this case market value being the closing
mid-market price of the Company's shares the day before the grant
was approved.
Share option grants are deemed accepted by the option holder
unless expressly rejected within a period of 30 days from the date
of grant.
Name Title Date of grant Total shares Percentage
of share options Number over which of issued
of share options shares
options are held under option
granted (post award)
20 October
Iain Ross Non-Executive Chairman 2021 200,000 200,000 0.35%
------------------------ ------------------- ---------- -------------- --------------
Chief Executive 20 October
Olav Hellebø Officer 2021 83,578 1,511,935 2.66%
------------------------ ------------------- ---------- -------------- --------------
Catherine Chief Financial 20 October
Isted Officer 2021 464,136 464,136 0.82%
------------------------ ------------------- ---------- -------------- --------------
The notifications set out below are provided in accordance with
the requirements of the EU Market Abuse Regulation and provide
further detail.
S
Contacts:
ReNeuron www.reneuron.com/investors
Olav Hellebø, Chief Executive Via Walbrook PR
Officer
Catherine Isted, Chief Financial Officer
Stifel Nicolaus Europe Limited (NOMAD
and Joint Broker)
Ben Maddison, Stewart Wallace +44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Stefano Aquilino (Sales & Corporate
Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407 804
Paul McManus / Alice Woodings 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead cell therapy candidate is in clinical
development for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that treat
diseases of the brain. The Company also has the ability through its
conditionally immortalised induced pluripotent stem cell (iPSC)
platform to make any tissue cells of choice; in-house programmes
are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
(Disclosure in relation to share options granted to Directors
and PDMRs)
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Iain Ross
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Non-Executive Chairman
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the Grant of share options
transaction
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 100,000
107p 100,000
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 20 October 2021
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Olav Hellebo
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 83,578
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 20 October 2021
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Catherine Isted
-------------------------------------- ---------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position/status Chief Financial Officer
-------------------------------------- ---------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------------------- ---------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ReNeuron Group plc
-------------------------------------- ---------------------------------
b) LEI 2138003TU12CQ5TZO137
-------------------------------------- ---------------------------------
4 Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv) each place where transactions have been conducted
-------------------------------------------------------------------------
a) Description of Ordinary Shares 1p
the financial instrument, RENE - GB00BF5G6K95
type of instrument
Identification
code
-------------------------------------- ---------------------------------
b) Nature of the transaction Grant of share options
-------------------------------------- ---------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
1p 232,068
94.8p 232,068
----------
-------------------------------------- ---------------------------------
d) Aggregated information N/A
-------------------------------------- ---------------------------------
e) Date of the transaction Granted 20 October 2021
-------------------------------------- ---------------------------------
f) Place of the transaction Outside a trading venue
-------------------------------------- ---------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHMZMMGZLFGMZZ
(END) Dow Jones Newswires
October 20, 2021 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Reneuron (LSE:RENE)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
